TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32380271
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered at weeks 0, 2, and 6
Study: 32380271
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline control) administered at weeks 0, 2, and 6
Study: 35786572
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by one implant
Study: 35786572
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by two implants
Study: 32916128
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg
Study: 36173649
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide capsules (OOC) at 60 mg/d, with option to titrate to 40 or 80 mg/d
Study: 35840876
Drug: Bilateral paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral paravertebral block (PVB) with 20 mL of ropivacaine 0.375% before incision
Study: 36153226
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (DYD), total daily dose 40 mg
Study: 36153226
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (VAG), total daily dose 180 mg
Study: 36153226
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (IMP), total daily dose 100 mg
Study: 32423467
Drug: Three treatment-shortening
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatment-shortening strategies
Study: 32423467
Drug: Adjunctive ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive ribavirin
Study: 32423467
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjunctive ribavirin)
Study: 35001215
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) 4.5 mg orally at night, N=54
Study: 32640411
Drug: Dissociative seizures-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissociative seizures-specific cognitive behavioral therapy (CBT)
Study: 33927413
Drug: BPN14770 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPN14770 25 mg twice daily
Study: 32560681
Drug: Residential Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Care Settings/Treatment as Usual (RCS/TAU)
Study: 33452561
Drug: Normal prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal prophylactic antibiotic treatment given only on the day of surgery (Group A)
Study: 33452561
Drug: Prolonged antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotic treatment given for 1 week after surgery (Group B)
Study: 32899959
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PRP and minoxidil
Study: 35010953
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng (AG) extract (1.6 g/day)
Study: 35673488
Drug: 220 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg/d ZnSO4 for 8 weeks
Study: 37696275
Drug: Avacincaptad pegol
Normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacincaptad pegol 2 mg
Study: 32882310
Drug: Avacincaptad pegol
Normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacincaptad pegol 4 mg
Study: 33208345
Drug: Tocilizumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (6 monthly infusions)
Study: 35909321
Drug: Medicines at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicines at Transitions of care Intervention (MaTI) including a patient-held My Medicines Toolkit, enhanced communication with community pharmacists, and increased engagement of community pharmacists post-discharge.
Study: 34166370
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 750 mg twice/day (n = 119)
Study: 34166370
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 75 to 125 mg/day (n = 114)
Study: 32532262
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy (HFNT) during early pulmonary rehabilitation
Study: 35487978
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using PREVENA dressings applied for 7 days
Study: 34724172
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg bimatoprost implant
Study: 34724172
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg bimatoprost implant
Study: 34724172
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate 0.5% (Control)
Study: 34724172
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (Control)
Study: 32234665
Drug: Trametinib daily
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib daily (arm 1)
Study: 32234665
Drug: Fluoropyrimidine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine therapy (infusional 5‐fluorouracil or oral capecitabine, arm 2)
Study: 32921595
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (including atherectomy, drug coated balloons, stenting)
Study: 33914047
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil plus trandolapril
Study: 33274552
Drug: Dietary fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish oil supplementation in mice; no specific dosage or duration mentioned.
Study: 33274552
Drug: Dietary fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish oil supplementation in humans with overweight or obesity; no specific dosage or duration mentioned.
Study: 36189668
Drug: Pupillometry-controlled administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pupillometry-controlled administration of sufentanil
Study: 36189668
Drug: Free-choice administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-choice administration of sufentanil by anesthesiologists
Study: 35475852
Drug: methylaminolevulinate photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylaminolevulinate photodynamic therapy
Study: 35475852
Drug: Severe AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe AK (Olsen grade III) with additional treatment
Study: 35727586
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2-90) plus aspirin (75-300 mg on day 1 followed by 75 mg daily for 21 days)
Study: 35727586
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1 followed by 75 mg daily on days 2-90) plus aspirin (75-300 mg on day 1 followed by 75 mg daily for 21 days)
Study: 35727586
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and aspirin
Study: 34531495
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy
Study: 34230018
Drug: face‐to‐face CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: face‐to‐face CBT treatment
Study: 32674009
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) with usual care (exercise and orthotic support)
Study: 34491840
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine administered one day before exposure to hyperopic blur
Study: 34491840
Drug: Placebo/hyperopic blur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/hyperopic blur one day after administration of 0.01% atropine
Study: 33404997
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter defibrillators (S-ICDs)
Study: 33460198
Drug: Gabapentin Enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin Enacarbil Extended-Release (GE-XR) 600 mg twice-a-day
Study: 34562391
Drug: Amoxicillin 50
Normalized name: amoxicillin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 50 mg/kg per day for 7 days
Study: 33413034
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (TG) - 15 weeks of combined aerobic exercise and strength training, 90-min supervised sessions weekly, encouraged home-based training 30 min/week
Study: 32579859
Drug: Telepractice voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepractice voice therapy
Study: 34271952
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care supplemented by five group-based cognitive therapy sessions performed by trained CR nurses
Study: 35550508
Drug: 1-year low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-year low-dose metronomic methotrexate-based chemotherapy
Study: 34519620
Drug: fSKEPT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: fSKEPT with conflict-related treatment focus
Study: 35897358
Drug: Standard Conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Conservative Treatment
Study: 35897358
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LLLT and Standard Conservative Treatment
Study: 32578032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IVF and ICSI on sibling oocytes
Study: 32406383
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game intervention during intravenous cannulation
Study: 34292258
Drug: StandingTall, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: StandingTall, a home-based fall prevention program delivered through a tablet computer
Study: 32926247
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg at weeks 0, 4, then every 8 weeks through week 52
Study: 32926247
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg
Study: 33965414
Drug: Pretarsal (PTS)
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretarsal (PTS) BoNT‐A injection
Study: 33965414
Drug: Preseptal (PST)
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preseptal (PST) BoNT‐A injection
Study: 33965414
Drug: Both PTS
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PTS and PST BoNT‐A injections
Study: 33380579
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine (5 μg) with 8 mg bupivacaine
Study: 33380579
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (2.5 μg) with 8 mg bupivacaine
Study: 35389015
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser with 1% terbinafine cream
Study: 35389015
Drug: Itraconazole (one-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (one-week pulse therapy)
Study: 34245857
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) > 3.33 mg/l
Study: 34986394
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose rNAPc2
Study: 34986394
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose rNAPc2
Study: 34986394
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (rNAPc2 and Heparin)
Study: 33601732
Drug: Computer-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based Cognitive Behavioral Therapy (CCBT) with therapeutic support
Study: 33368499
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg/day
Study: 34853915
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine single buccal infiltration
Study: 34853915
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine routine buccal and palatal injections
Study: 36192565
Drug: Aceclofenac controlled-release
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac controlled-release (CR) 200 mg once-a-day for 4 weeks
Study: 35961278
Drug: 2000 µg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 µg/wk of vitamin B12 supplementation for 90 days
Study: 32424486
Drug: Continuous basal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous basal infusion of 0.15% levobupivacaine at 3 ml/h (group C)
Study: 32424486
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent boluses of local anesthetic (12 ml every 4 h) (group PIB)
Study: 32435967
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention to increase dietary intake during chemotherapy
Study: 32435967
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein intake (< 0.8 g kg-1 day-1) before chemotherapy
Study: 32435967
Drug: 5.0-9.9% weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0-9.9% weight loss before chemotherapy
Study: 36858059
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with a reduced dose of 60 Gy and concurrent weekly cisplatin in N+ patients
Study: 36858059
Drug: Trans-oral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-oral surgery (TOS) and neck dissection (ND) with adjuvant reduced-dose RT depending on pathologic findings
Study: 32142578
Drug: Control (implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (implants placed in native bone)
Study: 34309223
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SDNN and rMSSD
Study: 32978014
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT) to the prostate
Study: 35349129
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of dexamethasone
Study: 32819864
Drug: Kinesiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiotherapy treatment protocol (KTP)
Study: 33988708
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (5 sessions, 60-90 minutes each, separated by 4 days)
Study: 33988708
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control (no additional treatment)
Study: 32862667
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months)
Study: 32959590
Drug: Fire needling
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needling bloodletting, applied twice a week for 4 weeks
Study: 35670414
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone (1 g) and metronidazole (500 mg) 30–60 min before incision
Study: 35670414
Drug: Multiple-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose ceftriaxone and metronidazole followed by cefuroxime and metronidazole for 5 days
Study: 35670414
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone and metronidazole
Study: 32519782
Drug: DAA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA group (509 patients who achieved sustained virological response after DAA therapy)
Study: 32662862
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.2 g/d from randomization to 36 weeks' postmenstrual age)
Study: 35024838
Drug: Fosfomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (4 g every 6 hours)
Study: 33835939
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SNF472
Study: 33835939
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg SNF472
Study: 34561142
Drug: Hepa-B vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepa-B vaccine
Study: 34020737
Drug: Oral motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral motor intervention (OMI)
Study: 33427884
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment performed by Associate Clinicians (ACs)
Study: 33427884
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment performed by Medical Doctors (MDs)
Study: 33591142
Drug: Laryngeal Mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal Mask Airway LMA‐Supreme™ (LMAS) placement with neuromuscular blocking agents (NMBAs)
Study: 33591142
Drug: Laryngeal Mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal Mask Airway LMA‐Supreme™ (LMAS) placement without neuromuscular blocking agents (NMBAs)
Study: 33629251
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens (platinum-based therapy)
Study: 36337878
Drug: Anti-arrhythmic drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arrhythmic drug (AAD)
Study: 32350686
Drug: Other potential
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other potential drugs
Study: 35103022
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Therapy with Interoceptive Exposure (GCBT-IE)
Study: 34107512
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g·kg‐1·d‐1) during resistance training (3 d·wk‐1 for 1 yr)
Study: 34369941
Drug: IANB, IANB
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB, IANB plus buccal infiltration, IANB plus lingual infiltration
Study: 33126910
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg once daily for 10 days)
Study: 33126910
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg once daily for 10 days)
Study: 33126910
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Atorvastatin with conventional therapy
Study: 32918160
Drug: SLH formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLH formulations (SLH-A and SLH-B)
Study: 32918160
Drug: SLH formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLH formulations
Study: 32741642
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg preoperatively
Study: 35444232
Drug: BenMel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BenMel (200 mg/m2 bendamustine + 100 mg/m2 melphalan)
Study: 35444232
Drug: Mel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mel (200 mg/m2 melphalan)
Study: 32605697
Drug: Injected allergen-specific
Normalized name: silk allergenic extract Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected allergen-specific immunotherapy (AIT) for grass pollen allergy
Study: 32700389
Drug: Physician incentives
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician incentives of $50 per patient per drug class
Study: 37173792
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Study: 34008397
Drug: Bedtime levothyroxine
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime levothyroxine administration (group A)
Study: 34008397
Drug: Early morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early morning levothyroxine administration (group B)
Study: 32790913
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + Clavulanic acid
Study: 32790913
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + Clavulanic acid + Probiotics
Study: 32790913
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics or probiotics (Control)